ClinicalTrials.Veeva

Menu

Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)

Organon logo

Organon

Status and phase

Completed
Phase 3

Conditions

Asthma, Exercise-Induced

Treatments

Drug: Comparator: Placebo
Drug: Comparator: Montelukast

Study type

Interventional

Funder types

Industry

Identifiers

NCT00092131
0476-270
MK0476-270
2004_026

Details and patient eligibility

About

The purpose of this study is to determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in participants who have a history of worsening asthma after exercise.

Enrollment

51 patients

Sex

All

Ages

15 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants with mild-to-moderate asthma

Exclusion criteria

  • Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

51 participants in 2 patient groups

1
Experimental group
Description:
Montelukast - Placebo
Treatment:
Drug: Comparator: Placebo
Drug: Comparator: Montelukast
2
Experimental group
Description:
Placebo - Montelukast
Treatment:
Drug: Comparator: Placebo
Drug: Comparator: Montelukast

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems